N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-3-[(Z)-[(5Z)-4-methyl-3,6-dioxo-5-(phenylmethylene)piperazinylidene]methyl]benzamidehydrochloride manufacturers
|
| | N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-3-[(Z)-[(5Z)-4-methyl-3,6-dioxo-5-(phenylmethylene)piperazinylidene]methyl]benzamidehydrochloride Basic information |
| Product Name: | N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-3-[(Z)-[(5Z)-4-methyl-3,6-dioxo-5-(phenylmethylene)piperazinylidene]methyl]benzamidehydrochloride | | Synonyms: | N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-3-[(Z)-[(5Z)-4-methyl-3,6-dioxo-5-(phenylmethylene)piperazinylidene]methyl]benzamidehydrochloride;XR 9051 HCl;XR9051 (hydrochloride);3-[(Z)-[(5Z)-5-benzylidene-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]-N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]benzamide:hydrochloride;XR9051 Hydrochloride,XR-9051 Hydrochloride | | CAS: | 180422-22-4 | | MF: | C39H39ClN4O5 | | MW: | 679.21 | | EINECS: | | | Product Categories: | | | Mol File: | 180422-22-4.mol | ![N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-3-[(Z)-[(5Z)-4-methyl-3,6-dioxo-5-(phenylmethylene)piperazinylidene]methyl]benzamidehydrochloride Structure](CAS/GIF/180422-22-4.gif) |
| | N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-3-[(Z)-[(5Z)-4-methyl-3,6-dioxo-5-(phenylmethylene)piperazinylidene]methyl]benzamidehydrochloride Chemical Properties |
| storage temp. | Store at -20°C |
| | N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-3-[(Z)-[(5Z)-4-methyl-3,6-dioxo-5-(phenylmethylene)piperazinylidene]methyl]benzamidehydrochloride Usage And Synthesis |
| Uses | XR9051 hydrochloride is an orally active and specific modulator of P-glycoprotein-mediated multidrug resistance (MDR)[1]. | | in vivo | XR9051 (20-40 mg/kg, ip) shows significant modulatory activity in mice bearing MDR human ovarian (2780AD and CH1/DOXr) and SCLC (H69/LX) xenografts[2].
| Animal Model: | Female Balb/c mice (20-25 g)[2]. | | Dosage: | I.V. | | Administration: | 20 mg/kg at various times (5 min to 24 h). | | Result: | The area under the concentration time curves (AUC) from time 0-∞ for plasma was 11.9 μg. h mL-1. The ratio between AUC for tissue:plasma for liver, heart and brain were 79.6, 16.9 and 0.3 respectively. |
| Animal Model: | MDR 2780AD ovarian carcinoma xenografts[2]. | | Dosage: | I.P. | | Administration: | 20, 30, 40 mg/kg daily with Epirubicin i.v. (10 mg/kg). | | Result: | Significantly reduced growth rate of MDR 2780AD ovarian carcinoma xenografts compared with either drug alone. |
| | References | [1] I L Dale , et al. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br J Cancer. 1998 Oct;78(7):885-92. DOI:10.1038/bjc.1998.597 [2] P Mistry, et al. In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance. Br J Cancer. 1999 Apr;79(11-12):1672-8. DOI:10.1038/sj.bjc.6690267 |
| | N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-3-[(Z)-[(5Z)-4-methyl-3,6-dioxo-5-(phenylmethylene)piperazinylidene]methyl]benzamidehydrochloride Preparation Products And Raw materials |
|